• Fri frakt över 249 kr
  • •
  • Snabba leveranser
  • •
  • Billiga böcker
Kundservice

Du är på sajten för privatpersoner.

Företag, bibliotek eller offentlig verksamhet?

Du handlar på classic.bokus.com, där alla dina funktioner finns intakta.
Till classic.bokus.com
Bokus logotyp. Gå till startsidan.
  • Erbjudanden
  • Nyheter
  • Student
  • Topplistor
  • Barn & ungdom
  • Bokus Play
  • E-böcker
  • Pocketböcker
  • Spel & pussel

10% rabatt på allt med kod: NYSTART10 →

Sidfot

Mina sidor

    Hjälp

    • Kundservice
    • Vanliga frågor och svar
    • Frakt och leverans
    • Retur vid ångerrätt
    • Reklamera vara
    • Betalning
    • Köpvillkor
    • Allmänna villkor
    • Information om webbplatsens tillgänglighet

    Om Bokus

    • Om oss
    • Pressrum
    • För studenter
    • För företag
    • För bibliotek och offentlig verksamhet
    • För leverantörer
    • Hållbarhet

    Populärt

    • Aktuella erbjudanden
    • Presentkort
    • Studentlitteratur
    • Nya böcker
    • Topplistor
    • Signerade böcker
    • Engelska böcker

    Inspiration

    • Boktips
    • BookTok
    • Populära bokserier
    • Barnbokskaraktärer
    • Populära författare
    Logotyp för Bokus
    Följ oss på Facebook (extern länk)Följ oss på Instagram (extern länk)Följ oss på YouTube (extern länk)Följ oss på TikTok (extern länk)
    bokus @ CookiesAnpassa cookiesIntegritetspolicyKöpvillkor
    Till Citymail hemsida (extern länk)Till Budbee hemsida (extern länk)Till Postnord hemsida (extern länk)Till Schenker hemsida (extern länk)Till Early Bird hemsida (extern länk)Till Walleys hemsida (extern länk)
    1. Medicin
    2. Medicin: icke kliniska discipliner
    3. Fysiologi

    Paraneoplastic Neurologic Disorders

    Inbunden, Engelska, 2024

    Del 200 i serien Handbook of Clinical Neurology

    2 766 kr

    Beställningsvara. Skickas inom 5-8 vardagar. Fri frakt över 249 kr.

    Beskrivning

    Paraneoplastic Neurological Disorders, Volume 200 covers new, recent descriptions of autoantibodies against neuronal cell surface antigens (only partly associated with paraneoplastic disorders) and the introduction of new immuno-oncological drugs that can contribute to diseases that are pathogenetically indistinguishable from paraneoplastic syndromes. Besides investigating the pathogenetic mechanisms of these disorders, this book also explores what the introduction of new drugs used in immune checkpoint inhibitor cancer therapy are teaching us in terms of immunopathogenesis. Following sections present individual syndromes (phenotypical clinical manifestations) of the CNS, PNS, NMJ, and muscle.

    Finally, the book investigates the role of antibody markers that differentiate by cytoplasmic, nuclear, and neuronal cell surface reactivities. Side effects of the new immuno-oncological drugs increasingly used in cancer therapy are also covered.



    • Profiles paraneoplastic diseases by tumor type
    • Identifies the pathogenetic mechanisms of PNS and provides epidemiological analysis
    • Presents individual syndromes of the CNS, PNS, NMJ, and muscle
    • Investigates the role of antibody markers
    • Differentiates cytoplasmic, nuclear, and neuronal cell surface reactivities
    • Discusses immune-oncological drugs causing diseases that are indistinguishable from PNS
    • Reviews therapeutic strategies and clinical approach to PNS patients

    Produktinformation

    • Utgivningsdatum:2024-04-25
    • Mått:192 x 262 x 32 mm
    • Vikt:1 330 g
    • Format:Inbunden
    • Språk:Engelska
    • Serie:Handbook of Clinical Neurology
    • Antal sidor:496
    • Förlag:Elsevier Science
    • ISBN:9780128239124

    Utforska kategorier

    • Fysiologi inom Medicin
    • Medicinsk utrustning och medicinska tekniker inom Medicin
    • Biovetenskap inom Naturvetenskap och teknik

    Mer om författaren

    - Head, Department of Neurology, Azienda Provinciale per I Servizi Sanitari (APSS) and University of Trento - Santa Chiara Hospital - 33100 TRENTO- Coordinator of a European Commission project on Paraneoplastic Neurological Syndromes (Concerted Action –PNS EURONETWORK – Fifth Framework Programme QLG1-CT-2002-01756).- Coordinator of a Specific Support Action of the European Commission on Paraneoplastic Neurological Syndromes (Sixth Framework Programme LSSM-CT-2005-518174). - Former Vice President of the Italian Neurological Society (SIN) Sean Pittock, M.D., is a consultant in the Department of Neurology and has a joint appointment in the Department of Laboratory Medicine and Pathology. He holds the academic rank of professor of neurology, Mayo Clinic College of Medicine. He currently serves as director of the Neuroimmunology Laboratory and is the Marilyn A. Park and Moon S. Park, M.D., Director of the Center for Multiple Sclerosis and Autoimmune Neurology. He joined the staff of Mayo Clinic in 2005.Dr. Pittock’s research and clinical interests include autoimmune neurological disorders, paraneoplastic diseases, neuromyelitis optica and multiple sclerosis. His research focuses on the diagnosis and treatment of multiple sclerosis and autoimmune disorders that target the central and peripheral nervous systems. He founded the Autoimmune Neurology Clinic at Mayo Clinic in 2006, which has allowed the development of a unique translational practice extending the laboratory's serological findings directly from bench to bedside. He has been involved in cutting edge trials of novel immunotherapies to treat NMO and other autoimmune neurologic diseases. He has been invited to give over 100 presentations on his research and has authored over 275 journal articles, abstracts and other written publications.He is currently the Chair of the Autoimmune Neurology Special Interest Group at the American Neurological Association and directs the educational program on Neuromyelitis Optica at the American Academy of Neurology.Dr. Pittock serves on numerous professional societies and associations, including the Minnesota Medical Association and American Academy of Neurology, and is a committee member of the American Neurological Association.

    Innehållsförteckning

    • Section I. Introduction and Overview1. Introduction and overview of immunopathological mechanisms and future directions2. Changing landscape in the field of paraneoplastic neurology: Personal Perspectives over a 35-year career3. Pathogenesis and immunopathology of paraneoplastic disordersSection II. Paraneoplastic neurological syndromes4. Epidemiology of paraneoplastic neurologic syndromes5. Clinical approach to diagnosis of paraneoplastic neurological syndromes6. Overview of treatment strategies in paraneoplastic neurological syndromes7. Methods to Detect Paraneoplastic Antibodies8. Paraneoplastic encephalitis9. Autoimmune and paraneoplastic seizures 10. Paraneoplastic Cerebellar and Brainstem Disorders11. Paraneoplastic/autoimmune myelopathies12. Paraneoplastic vision loss13. Paraneoplastic movement disorders14. Movement disorders associated with pediatric encephalitis15. Paraneoplastic neuropathies and peripheral nerve hyperexcitability disorders16. Paraneoplastic autonomic neuropathies and GI dysmotility 17. Myasthenia Gravis – Pathophysiology, diagnosis and treatment18. Lambert-Eaton myasthenic syndrome19. Paraneoplastic myopathiesSection III. Paraneoplastic autoantibodies20. Intracellular paraneoplastic autoantibodies21. Antibodies to neural cell surface and synaptic proteins in paraneoplastic neurologic syndromes22. Optimizing the diagnostic performance of neural antibody testing for paraneoplastic and autoimmune encephalitis in clinical practiceSection IV. Paraneoplastic neurological and autoantibody accompaniments of cancer23. Paraneoplastic Autoimmune Neurological Disorders associated with Thymoma24. Paraneoplastic Neurologic Manifestations of Neuroendocrine tumors25. Paraneoplastic Neurological Syndrome associated with Gynaecological and Breast malignancies26. Hematological malignancies and hematopoietic stem cell transplantation27. Paraneoplastic neurological syndrome and autoantibody accompaniments of germ cell tumorsSection V. Neurological complications of cancer immunotherapy28. Neurological manifestations of autoimmunity with immune checkpoint inhibitors